Syensqo and Emulseo Announce Groundbreaking Partnership to Revolutionize Microfluidic Technology for Healthcare Applications

[Location], [Date] - Syensqo, a leading specialty chemicals company, has announced a strategic partnership with Emurseo, a French company specializing in formulations for microfluidic technology. The collaboration aims to drive advancements in microfluidic technologies, particularly for healthcare applications.

With the inclusion of Syensqo's proprietary Galden PFPE solution in Emurseo's Fluo-Oil range of products, customers will be provided with an essential component for creating reliable and performant droplet-based microfluidic analyses. This partnership is expected to enhance the adoption of microfluidic technology in healthcare and industrial applications.

Microfluidic technologies have gained significant attention in recent years due to their vast applications in precision medicine, diagnostics, and drug development. The collaboration between Syensqo and Emurseo will focus on developing innovative solutions for healthcare applications, including cancer diagnosis, antibody production, and rapid COVID-19 testing.

"Galden PFPE is an exceptional chemical inertness and performance," said Peter Browning, President of the Specialty Polymers Global business unit at Syensqo. "We are thrilled to partner with Emulseo to expand its applications beyond traditional electronic industry and contribute to life-saving treatments such as cancer diagnosis."

Emurseo CEO, Florine Maes emphasized, "This partnership demonstrates our commitment to innovative technologies in the health sector and further solidifies our position as a thought leader. Syensqo's high-performance chemicals combined with our expertise will enable us to provide unparalleled solutions for customers worldwide".

The collaboration between Syensqo and Emurseo is set to revolutionize microfluidic technology in healthcare, bringing forth innovative solutions for disease diagnosis, treatment, and personalized medicine.